Updated survival, response and safety data in a phase 1 dose-finding study (CA209-004) of concurrent nivolumab (NIVO) and ipilimumab (IPI) in advanced melanoma

被引：0
|
作者：
Sznol, Mario [1 ,2 ]
Callahan, Margaret K. [3 ]
Kluger, Harriet [1 ,2 ]
Postow, Michael A. [3 ,4 ]
Gordan, RuthAnn [3 ]
Segal, Neil H. [3 ]
Rizvi, Naiyer A. [3 ]
Lesokhin, Alexander [3 ]
Atkins, Michael B. [5 ]
Kirkwood, John M. [6 ]
Burke, Matthew M. [1 ,2 ]
Ralabate, Amanda [1 ,2 ]
Rivera, Angel [1 ,2 ]
Kronenberg, Stephanie A. [3 ]
Agunwamba, Blessing [3 ]
Ruisi, Mary [7 ]
Horak, Christine [8 ]
Jiang, Joel [7 ]
Wolchok, Jedd [3 ]
机构：
[1] Yale Univ, Sch Med, New Haven, CT USA
[2] Yale New Haven Med Ctr, Smilow Canc Ctr, New Haven, CT USA
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Weill Cornell Med Coll, New York, NY USA
[5] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[6] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[7] Bristol Myers Squibb, Princeton, NJ USA
[8] Bristol Myers Squibb, Lawrenceville, NJ USA
来源：
JOURNAL OF TRANSLATIONAL MEDICINE | 2016年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
O4
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients with advanced melanoma (CheckMate 067)
    Larkin, James
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Rutkowski, Piotr
    Grob, Jean-Jacques
    Cowey, C. Lance
    Lao, Christopher D.
    Schadendorf, Dirk
    Ferrucci, Pier Francesco
    Smylie, Michael
    Dummer, Reinhard
    Hill, Andrew
    Haanen, John
    Maio, Michele
    McArthur, Grant
    Walker, Dana
    Rollin, Linda
    Horak, Christine
    Hodi, F. Stephen
    Wolchok, Jedd D.
    CANCER RESEARCH, 2017, 77
  • [32] Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).
    Schadendorf, Dirk
    Ascierto, Paolo Antonio
    Haanen, John B. A. G.
    Espinosa, Enrique
    Demidov, Lev V.
    Garbe, Claus
    Lorigan, Paul
    Gogas, Helen
    Hoeller, Christoph
    Guren, Tormod Kyrre
    Rorive, Andree
    Rutkowski, Piotr
    Munoz-Couselo, Eva
    Dummer, Reinhard
    Carneiro, Ana
    Hospers, Geke
    Grigoryeva, Elena Borisovna
    Bhore, Rafia
    Nathan, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069).
    Hodi, F. Stephen
    Postow, Michael Andrew
    Chesney, Jason Alan
    Pavlick, Anna C.
    Robert, Caroline
    Grossmann, Kenneth F.
    McDermott, David F.
    Linette, Gerald P.
    Meyer, Nicolas
    Giguere, Jeffrey K.
    Agarwala, Sanjiv
    Shaheen, Montaser F.
    Ernstoff, Marc S.
    Minor, David R.
    Salama, April K.
    Taylor, Matthew H.
    Ott, Patrick Alexander
    Jiang, Joel
    Gagnier, Paul
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [34] Patient-reported quality of life (QoL) of advanced melanoma patients in a Phase 3 study of nivolumab (NIVO) with or without ipilimumab (IPI) versus IPI: CheckMate 067 4-year data.
    Schadendorf, Dirk
    Larkin, James M. G.
    Wolchok, Jedd D.
    Chiarion-Sileni, Vanna
    Taylor, Fiona
    Lawrance, Rachael
    Moreno-Koehler, Alejandro
    Lord-Bessen, Jennifer
    Rizzo, Jasmine I.
    Moshyk, Andriy
    Kotapati, Srividya
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] Overall survival and safety experience from an expanded access program (EAP) of nivolumab (NIVO) for patients with advanced melanoma (MEL) who progressed after prior ipilimumab (IPI) treatment
    Barros e Silva, Milton
    Schmerling, Rafael
    de Melo, Andreia Cristina
    Azevedo, Sergio
    Garicochea, Bernardo
    McWhirter, Elaine
    Smylie, Michael
    Gifoni, Markus
    dos Anjos, Carlos Henrique
    Petrella, Teresa
    Chacon, Matias
    Greco, Martin
    Nair, Suresh
    Avila, Alexandre
    Demelo, Sheena
    Jiang, Joel
    Ernst, Scott
    CANCER RESEARCH, 2017, 77
  • [36] Assessment of real-world effectiveness of first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) or NIVO monotherapy for advanced melanoma: A retrospective cohort study
    Freeman, M.
    Gupte-Singh, K.
    You, M.
    Le, T. K.
    Ritchings, C.
    Rao, S.
    Jang, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 457 - 457
  • [37] NRG BN002: SAFETY DATA FROM A PHASE I STUDY OF IPILIMUMAB (IPI), NIVOLUMAB (NIVO), AND THE COMBINATION FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Gilbert, Mark
    Zhang, Peixin
    Sloan, Andrew
    Aldape, Kenneth
    Wu, Jing
    Rogers, Lisa
    Wen, Patrick
    Barani, Igor
    Iwamoto, Fabio
    Raval, Raju
    Voloshin, Alfredo
    de Groot, John
    Won, Minhee
    Mehta, Minesh P.
    NEURO-ONCOLOGY, 2018, 20 : 7 - 7
  • [38] Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study
    Daver, Naval G.
    Garcia-Manero, Guillermo
    Basu, Sreyashi
    Cortes, Jorge E.
    Ravandi, Farhad
    Kadia, Tapan M.
    Konopleva, Marina Y.
    Jabbour, Elias J.
    DiNardo, Courtney D.
    Assi, Rita
    Pierce, Sherry A.
    Alvarado, Yesid
    Estrov, Zeev E.
    Pemmaraju, Naveen
    Takahashi, Koichi
    Ning, Jing
    Gonzalez, Graciela M. Nogueras
    Kornblau, Steven M.
    Alfayez, Mansour
    Matthews, Jairo
    Flores, Wilmer
    Blando, Jorge
    Allison, James P.
    Sharma, Padmanee
    Kantarjian, Hagop M.
    BLOOD, 2018, 132
  • [39] Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).
    Wolchok, Jedd D.
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Rutkowski, Piotr
    Grob, Jean Jacques
    Cowey, Charles Lance
    Lao, Christopher D.
    Schadendorf, Dirk
    Ferrucci, Pier Francesco
    Smylie, Michael
    Dummer, Reinhard
    Hill, Andrew Graham
    Haanen, John B. A. G.
    Maio, Michele
    McArthur, Grant A.
    Yang, Arvin
    Rollin, Linda
    Horak, Christine E.
    Larkin, James M. G.
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067)
    Wolchok, Jedd D.
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Rutkowski, Piotr
    Grob, Jean Jacques
    Cowey, Charles Lance
    Lao, Christopher D.
    Schadendorf, Dirk
    Ferrucci, Pier Francesco
    Smylie, Michael
    Dummer, Reinhard
    Hill, Andrew Graham
    Haanen, John B. A. G.
    Maio, Michele
    McArthur, Grant A.
    Yang, Arvin
    Rollin, Linda
    Horak, Christine E.
    Larkin, James M. G.
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18)
12345